Structural Biology and Drug Discovery of Difficult Targets: The Limits of Ligandability
Authors:
- Tom L. BlundellTBTom L. Blundell
- 1 January 2012
- journal article
- review article
- Published by Elsevier in Chemistry & Biology
- Vol. 19 (1) , 42-50
Abstract
No abstract availableKeywords
This publication has 90 references indexed in Scilit:
- A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53Cancer Cell, 2010
- 3did: identification and classification of domain-based interactions of known three-dimensional structureNucleic Acids Research, 2010
- The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizerNature Chemical Biology, 2010
- Direct inhibition of the NOTCH transcription factor complexNature, 2009
- An empirical framework for binary interactome mappingNature Methods, 2008
- A survey of available tools and web servers for analysis of protein-protein interactions and interfacesBriefings in Bioinformatics, 2008
- Reaching for high-hanging fruit in drug discovery at protein–protein interfacesNature, 2007
- Effects of the magnesium and chloride ions and shikimate on the structure of shikimate kinase fromMycobacterium tuberculosisActa Crystallographica Section F Structural Biology and Crystallization Communications, 2006
- Hot-spot mimicry of a cytokine receptor by a small moleculeProceedings of the National Academy of Sciences, 2006
- Insights into DNA recombination from the structure of a RAD51–BRCA2 complexNature, 2002